Patient access to medical cannabis will increase greatly in the coming weeks.
Georgia’s estimated 14,000 registered medical cannabis patients will soon be able to purchase cannabis products with low tetrahydrocannabinol (THC) oil at pharmacies in the state (1). About 120 pharmacies have already applied to sell the oil created by Botanical Science, one of the state’s two licensed producers (1). The Georgia Board of Pharmacy began accepting applications last week and requires inspections before granting approval (1).
In 2019 the General Assembly approved the distribution of low THC oil, and recently the board finalized and passed its rules regarding safety and distribution of the products. With last month’s approval by Governor Brian Kemp of these rules, Georgia is set to be the first state in the US to sell medical cannabis products at independent pharmacies (1).
“Pharmacists have been fielding questions from patients for years without ever having the ability to do anything about it,” said Gary Long, CEO for Botanical Sciences (1). “Finally, they have the ability not just to give people advice but provide them with the therapies they’ve been seeking.”
Within the coming weeks, independent pharmacies are anticipated to start offering low THC oil and it is estimated that nearly all of Georgia’s population will be within a half hour drive of a participating pharmacy (1). Registered patients will need to present their state-approved registry card, which must be obtained through a doctor’s approval (1). The THC oil can contain up to 5% THC (1).
“We’re going to have patients that need this health care in some remote parts of Georgia that probably would never have a dispensary near them,” said Jonathan Marquess, vice president for the Georgia Pharmacy Association and pharmacy owner (1). “But they do have a caring professional, a knowledgeable professional pharmacist, in their communities who can talk to them.”
Georgia approved the medical use of low THC products in 2015 and qualifying conditions include autism spectrum disorder, cancer, and Parkinson’s disease (2). Currently, patients are able to obtain cannabis through the state’s seven approved dispensaries, which were opened earlier this year (1).
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.